Updated October 13 at 1:13pm
46 results total, viewing 1 - 10
Mnemosyne Pharmaceuticals has changed its name to Luc Therapeutics and moved its headquarters from Providence to Cambridge. more
PROVIDENCE — The elements of a mixed-use project that could cover five acres of the former Interstate 195 land were revealed last week in a public overview by the development team. The project, a joint effort of CV Properties LLC of … more
Tivorsan Pharmaceuticals Inc. has named James E. Connolly CEO. The biotechnology company, which focuses on treating Duchenne Muscular Dystrophy and other neuromuscular disorders, also said that Connolly will serve as a member of its board. more
IlluminOss Medical has been issued two patents related to its internal bone fixing system, the company announced Tuesday. more
The Champlin Foundations awarded the University of Rhode Island three grants totaling $421,795 to purchase high-tech equipment to advance education and student learning. more
Nabsys Inc. has named Tony Shuber vice president and chief scientific officer in its latest move toward bringing its genome-mapping products to market. more
Mnemosyne Pharmaceuticals Inc. appointment of Vanessa King as president and CEO. more
Big Brothers Big Sisters of the Ocean State recently received a $30,000 Amgen Foundation Grant to develop and implement a Science, Technology, Engineering and Mathematics curriculum into the mentoring agency’s site-based programming. more
Medrobotics Corp. was named a “rising star” in the Smaller Business Association of New England Inc.’s 2015 New England Innovation Awards. more
Last week Nabsys Inc. shut its doors, costing approximately 40 people their jobs and investors about $50 million. That's the nature of the beast in the high-risk biotech field. But by some of the reaction to the company's failure, it is … more
1 | 2 | 3 | 4 | 5 Next »